纳米雄黄对人宫颈癌细胞增殖、凋亡及HPVE6/E7的影响
摘要
目的：探讨纳米雄黄对不同宫颈癌细胞株Hela(HPV18阳性,腺癌),Caski (HPV16阳性,鳞癌),C33A (HPV阴性,腺癌)增殖、凋亡及其对HPV16/18E6、E7mRNA及E6、E7蛋白的影响。
方法：体外培养三种不同宫颈癌细胞,采用不同质量浓度(5,10,20,40ug/ml)纳米雄黄作用于不同宫颈癌细胞不同时间(24487296h)/(48h),相差显微镜下观察不同质量浓度组与对照组细胞形态学变化；MTT法测定药物对细胞生长的抑制作用；流式细胞仪检测细胞凋亡及细胞周期；实时荧光定量PCR法检测HPV16/18E6/E7mRNA的表达；免疫组化法检测HPV16/18E6/E7蛋白的表达。
结果：不同浓度纳米雄黄处理不同细胞株,均不同程度抑制细胞生长,促进细胞凋亡,具有时间浓度依赖性,其中对Caski细胞作用最强,对C33A细胞作用最弱；流式细胞仪检测结果表明,不同质量浓度的纳米雄黄可促进细胞凋亡,且呈浓度依赖性；细胞周期结果显示高质量浓度组(20,40ug/ml)对HPV阳性宫颈癌细胞有G2/M期阻滞；实时荧光定量PCR结果显示不同浓度纳米雄黄可不同程度抑制E6E7mRNA的表达,且随浓度增大,抑制作用增大,对E6基因的抑制作用强于E7基因,对于HPV16型E6E7mRNA的抑制作用强于HPV18型；免疫组化结果显示,E6E7蛋白定位于胞浆内,随着药物质量浓度的增加,蛋白表达量减少。
结论：纳米雄黄混悬液可抑制不同宫颈癌细胞株的增殖,促进细胞凋亡,其抑制细胞增殖、促进细胞凋亡的作用对Caski细胞最强,对Hela细胞次之,对C33A细胞相对最弱。对HPV阳性的细胞可产生G2/M期阻滞。纳米雄黄对宫颈癌细胞的增殖抑制及凋亡诱导作用可能与抑制E6E7基因及蛋白的表达有关,其中E6基因可能起主导作用。
Purposes:To investigate the proliferation inhibitory and apoptosis induction effects of nano-realgar on cervical cancer cell Caski (HPV16+, adeno carcinoma)、Hela (HPV18+, squmous carcinoma) and C33A (HPV-, adeno carcinoma).
Methods:Treat the cells with different concentration (5,10,20,40ug/ml) and time (24,48,72,96h)/(48h), observe the morphology under phase contrast microscope; MTT to test the growth inhibitory; flow cytometry to measure the percentage of apoptosis and different stages of cell cycles; real-time PCR for the measurement of the level of E6E7mRNA; immunohistochmistry for the detection of the level of E6and E7oncoprotein.
Results:The cells' growth rates was decreased and they got more apoptosis on an concentration-time dependened behavior, what is more, Caski cells seems more sensitive to the drug where as the C33A cells were the last sensitive one; The flow cytometry test shows that the nano-realgar could induce more apoptosis as the concentration increased (P<0.05); high concerntration (20,40ug/ml) of nano-realgar can induce G2/M stage block; Real time PCR shows the level of E6and E7mRNA was decreased in an concentration depended behavior and the E6gene was inhibited more that E7gene and so as both the E6and E7gene of HPV16to HPV18; IHC shows the E6and E7oncoprotein was decreased as the concentration of nano-realgar increased.
Conclusion:Nano-realgar can inhibit the growth and induce apoptosis on different kinds of cervical carcinoma cell line, the effects goes as follows Caski> Hela>C33A, it can also induce G2/M stage block on HPV positive cervical cancer cells when the concentration of drug is high enough (20,40ug/ml). The E6E7mRNA and oncoprotein may contribute to these effects, and E6may take the leading role.
方法：体外培养三种不同宫颈癌细胞,采用不同质量浓度(5,10,20,40ug/ml)纳米雄黄作用于不同宫颈癌细胞不同时间(24487296h)/(48h),相差显微镜下观察不同质量浓度组与对照组细胞形态学变化；MTT法测定药物对细胞生长的抑制作用；流式细胞仪检测细胞凋亡及细胞周期；实时荧光定量PCR法检测HPV16/18E6/E7mRNA的表达；免疫组化法检测HPV16/18E6/E7蛋白的表达。
结果：不同浓度纳米雄黄处理不同细胞株,均不同程度抑制细胞生长,促进细胞凋亡,具有时间浓度依赖性,其中对Caski细胞作用最强,对C33A细胞作用最弱；流式细胞仪检测结果表明,不同质量浓度的纳米雄黄可促进细胞凋亡,且呈浓度依赖性；细胞周期结果显示高质量浓度组(20,40ug/ml)对HPV阳性宫颈癌细胞有G2/M期阻滞；实时荧光定量PCR结果显示不同浓度纳米雄黄可不同程度抑制E6E7mRNA的表达,且随浓度增大,抑制作用增大,对E6基因的抑制作用强于E7基因,对于HPV16型E6E7mRNA的抑制作用强于HPV18型；免疫组化结果显示,E6E7蛋白定位于胞浆内,随着药物质量浓度的增加,蛋白表达量减少。
结论：纳米雄黄混悬液可抑制不同宫颈癌细胞株的增殖,促进细胞凋亡,其抑制细胞增殖、促进细胞凋亡的作用对Caski细胞最强,对Hela细胞次之,对C33A细胞相对最弱。对HPV阳性的细胞可产生G2/M期阻滞。纳米雄黄对宫颈癌细胞的增殖抑制及凋亡诱导作用可能与抑制E6E7基因及蛋白的表达有关,其中E6基因可能起主导作用。
Purposes:To investigate the proliferation inhibitory and apoptosis induction effects of nano-realgar on cervical cancer cell Caski (HPV16+, adeno carcinoma)、Hela (HPV18+, squmous carcinoma) and C33A (HPV-, adeno carcinoma).
Methods:Treat the cells with different concentration (5,10,20,40ug/ml) and time (24,48,72,96h)/(48h), observe the morphology under phase contrast microscope; MTT to test the growth inhibitory; flow cytometry to measure the percentage of apoptosis and different stages of cell cycles; real-time PCR for the measurement of the level of E6E7mRNA; immunohistochmistry for the detection of the level of E6and E7oncoprotein.
Results:The cells' growth rates was decreased and they got more apoptosis on an concentration-time dependened behavior, what is more, Caski cells seems more sensitive to the drug where as the C33A cells were the last sensitive one; The flow cytometry test shows that the nano-realgar could induce more apoptosis as the concentration increased (P<0.05); high concerntration (20,40ug/ml) of nano-realgar can induce G2/M stage block; Real time PCR shows the level of E6and E7mRNA was decreased in an concentration depended behavior and the E6gene was inhibited more that E7gene and so as both the E6and E7gene of HPV16to HPV18; IHC shows the E6and E7oncoprotein was decreased as the concentration of nano-realgar increased.
Conclusion:Nano-realgar can inhibit the growth and induce apoptosis on different kinds of cervical carcinoma cell line, the effects goes as follows Caski> Hela>C33A, it can also induce G2/M stage block on HPV positive cervical cancer cells when the concentration of drug is high enough (20,40ug/ml). The E6E7mRNA and oncoprotein may contribute to these effects, and E6may take the leading role.
引文
[1]WHO. World Health Organization Report:Comprehensive cervical cancer control:a guide to essential practice [R]. World Health Organization Web site, 2006,10(12):156-170.
[2]Parkin DM, Bray F, Ferlay J et al. Estimating the world cancer burden:globocan 2000 [J].Int J Cancer,2001,94:153-156.
[3]Jemal A, Bray F, Center MM, et al. Global cancer statiscs [J]. CA Cancer J Clin,2011,61(2):69-90
[4]You W, Dainty LA, Rose GS, et al. Gynecologic malignancies in women aged less than 25 years [J]. Obstet Gynecol,2005,105(8):1405-1409.
[5]zur Hausen, H., Papillomaviruses in the causation of human cancers-a brief historical account. Virology,2009.384(2):p.260-5.
[6]Walboommers JM,Jacobs MV,Manos MM,etal.Human papillomavirus is a necessary cause of invasive cancer worldwide[J].J Pathol,1999,189:12-19
[7]F ilippva M, Song H, Connolly JL, et al. The human papillomavirus 16 E6 protein binds to tumor necrosis factor(TNF) R1 and protects cell from TN F2induced apoptosis. BiolChem,2002; 277 (24):21730221739.
[8]Cary A. Moody and Laimonis A. Laimins. Human papillomavirus oncoproteins:pathways to transformation [J]. Nature:cancer,2010,10:550-560
[9]Niladri Ganguly, Suraj P Parihar. Human papillmavirus E6 and E7 oncoproteins as risk factors for tumorigenesis [J]. Biosci,2009,34(1):113-123
[10]Longworth MS,Laimins LA.Pathogenesis of human papillomaviruses in differerntiation epithelia [J]. Microbiol and Mol Biol Rev,2004,68(2):362-372
[11]Band V, Dalal S, et al. Enhanced degradation of P53 protein in HPV-6 and BPV-1 E6 immortalized human mammary epithelial cells [J]. EMBO,1993,12:1847-1852
[12]Crook T, Tidy J A, et al. Degradation of P53 can be targeted by HPV E6 sequences distinct from those required for P53 binding and trans-activation [J].Cell,1991,67:547-556
[13]Havre PA, Yuan J, et al.P53 inactivation by HPV 16 E6 results in increased mutagenesis in human cells [J].Cancer Res,1995,55:4420-4424
[14]Scheffner M, Huibregtse J M, et al.The HPV 16 E6 and E6-AP complex functions as a ubiquitin protein ligase in the ubiquitination of P53 [J].Cell,1993,75:495-505
[15]Scheffner M, Werness B A, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of P53 [J].Cell,1990,63: 1129-1136
[16]Werness B A, Levine A J, et al. Association of human papillomavirus types 16 and 18 E6 proteins with P53 [J].Science,1990,248:76-79
[17]Boyer S N, Wazer D E, Band V. E7 protein of human papillma virus 16 induces the degradation of retinoblastoma protein through ubiquitin-proteasome pathway [J].Cancer Res,1996,56:4620-4624
[18]Dyson N, Howley P M, et al. The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product [J].Science,1989,17:934-937
[19]Eichten A, Westfall M, et al. Stabilization and functional impairment of the tumor suppressor P53 by the human papillomavirus type 16 E7 oncoprotein [J]. Virology, 2002,12:2245-2262
[20]Jo H, Kim J W. Implications of HPV infection in uterine cervical cancer [J].Cancer Ther,2005,3:419-434
[21]Munger K, Howley P M. Human papillomavirus immortalization and transformation functions [J].Virus Res,2002,89:213-228
[22]Munger K, Baldwin A, et al. Mechanisms of human papillomavirus -induced oncogenesis [J].Virol,2004,78:11451-1460
[23]欧幸甘,罗小平等.宫颈癌的新辅助化疗研究进展[J].中国医疗前沿,2010,5(18)：14-16.
[24]Sardi JE, Boixadera MA, Sardi JJ. Neoadjuvant chemotherapy in cervical cancer:a new trend [J].Curt Opin Obstet Gynecol,2005,17(1):43-47.
[25]刘继红,熊樱.对宫颈癌新辅助化疗临床价值的评价[J].中国妇产科临床杂志,2008,9(3)：163-165
[26]苗华芹,周登光等.高危宫颈癌化疗进展[J].实用癌症杂志,2005,20(3)：332-334.
[27]Cai HB, Chen HZ, Yin HH. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical caneer [J]. J Obstet Gynecol Res,2006,32: 315-323.
[28]Sardi JE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage I b squamous carcinoma of the cervix: the final results [J]. Gynecol Onc01,1997,67:61-69.
[29]陈明晖,巫岳鹏.宫颈癌化疗临床研究新进展[J].中国妇幼保健,2005,20：150-1154
[30]Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer:a systematic review and meta analysis of individual patient data from 21 randomised trials [J]. Eur J Cancer,2003,39(17):2470-2486.
[31]Fracasso PM, Blessing JA, Wolf J, et al. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix:a gynecologic oncology group study [J]. Gynecol Oncol,2003,90(1):177-180.
[32]Ya Cao, Ronald A.DePinho, Matthias Ernst, et al. Cancer research:past, present and future [J]. Nature Reviews:cancer,2011,11:749-757
[33]姚志华,张明智.中药抗恶性肿瘤研究进展[J].现代肿瘤医学,2006,14(4)：503-505.
[34]孙端,朱燕飞. 抗肿瘤中药治疗癌症临床概况. [J]. 海峡药学,2010,22(11)：146-148
[35]梁莉,刘叙仪,王洁,等.马蔺子素对耐顾铂人肺腺癌细胞系A549DDP耐药逆转及可能的机制[J].中华医学杂志.2001,81(22)：1392-1393.
[36]林华型.灵芝多糖抗肿瘤靶向作用机制研究进展[J].细胞与分子免疫学杂志,2007.24(4)：428-429.
[37]吕淑华.黄芪多糖抗肿瘤作用研究进展[J].江西中医学院学报,2009,21(1)：85-87.
[38]丁杰龙.川牛膝多糖的抗肿瘤作用初探[J].中国民族民间医药杂志,2009.18(13)：46-47.
[39]张舰,王维民.刘延庆,许运明.南蛇藤提取物体内抗肿瘤作用的实验研究[J].中国中药杂志,2006.31(18)：1514-1516.
[40]陶伟.中药半枝莲的药理及临床应用研究进展[J].海军医学杂志,2008,29(3)：181-184.
[41]陈思宇,李信民.刘陕西.含砷类中药在恶性血液病治疗中的研究概况[J].中国中药杂志,2000,25(8)：454-457.
[42]Lu DP, Qiu JY, Jiang B, et al. Tetrarsenic tetra-sulfide for the treatment of acute promyelocytic leukemia:A pilot report [J]. Blood,2002,99(9); 3136-3143.
[43]邵泽叶,等。纳米三硫化二砷对人骨髓增生异常综合征细胞株MUTZ-1作用的实验研究,中华血液学杂志,2009,1,30(1)：29-32.
[44]CHENSY, LI XM, LIU SX. Over view of the advance in the research of traditional chinese medicine containing arsenic for the treatment of malignant hematologic disease. [J]. China Journal of Chinese Materia Medica,2000,25(8).454-456.
[45]林梅,王子好,张东生.As2S3纳米粒的制备及其对肝癌SMMC-7721细胞的治疗作用.[J].东南大学学报(自然科学版),2006,36：298-302.
[46]王玉华,葛常辉,等.ABC家族基因在乳腺癌耐药细胞MCF-7／ADM中的表达及雄黄对其作用初探[J].解剖学报,2002,33(6)：623-626
[47]邹春芳,张祖贻。As2S2诱导肺腺癌细胞凋亡的实验研究[J].实用肿瘤杂志,2004,19(6)：507-510.
[48]张晨.雄黄对肝癌细胞系BEL-7042增生的影响[J].肝脏,2004,9(2)：112-113
[49]Yin Ling, et al. The Study of Cervical cancer Hela Cell Inhibition and Apoptosis Induced by As4S4 [J].Journal of Methematical Medicine,2007,20(6):785-787
[50]尹伶,濮德敏等.As4s4诱导宫颈癌Hela细胞凋亡及对端粒酶活性的影响[J].中国现代医学杂志,2008,18(3)：298-301
[51]Chen Wenxue,Zhang Feng, et al. The effect of realgar on apoptosis of transplanted ovarian SKOV3 carcinoma cells in nude mice [J].Tumor,2007.27(10):787-790
[52]王玉华,葛常辉。ABC家族基因在乳腺癌耐药细胞MCF-7/ADM中的表达及雄黄对其作用初探[J].解剖学报,2002,33(6)：623-626.
[53]Wang Yan,Qi Li,et al. Research advance of nanometric traditional chinese herbal drugs for cancer treatment [J]. Journal of chinese Integrative Medicine,2007,5(6):697-701
[54]董晓辉.纳米技术应用于中药研究与开发的思考[J].中国中医药信息杂志,2008,15(2)：3-5
[55]朱戈,王振洲等.纳米技术在生物医学领域的应用展望[J].中国医学装备,2011,8(5)：25-27
[56]叶星辰,陈燕忠等。纳米技术在中药新剂型研究中的应用。[J].中国现代药物应用,2011,5(2)：241-243
[57]Peter Balaz, Jan Sedlak.Arsenic in cancer treatment:Challenges for application of Realgar Nanoparticales [J].Toxins,2010,2,1568-1581
[58]詹秀琴,赵凤鸣,郭立玮.不同粒径雄黄对8MMC7721细胞凋亡的影响[J].中药药理与临床,2006,22(2)：44-46
[59]徐辉碧,杨祥良,等.雄黄抑制小鼠肉瘤S180的尺寸效应的初步研究[J].武汉大学学报(自然科学版),2000,46：288-289
[60]姜艳丽.纳米雄黄诱导HL-60诱导细胞凋亡的初步研究：[硕士学位论文],佳木斯：佳木斯大学,2005.
[61]Rong Liu, Demin PU, et al. Induction of SiHa Cells Apoptosis by Nanometer Realgar Suspension and Its Mechanism [J]. Huazhong Univ Sci Technol [Med Sci],2008,28(3):317-321.
[62]刘嵘,濮德敏,等.纳米雄黄混悬液对人宫颈癌细胞RCAS1表达的影响[J].中国医院药学杂志,2008,28(6)：459-462.
[63]孙晓辉.纳米雄黄及其固体分散体的制备和抗肿瘤作用初步观察：[硕士学位论 文].武汉：华中科技大学,2003.
[64]石焱.纳米雄黄的制备及药物代谢动力学研究：[硕士学位论文].广州：南方医科大学,2008.
[65]杨晓波.纳米雄黄的制备及其药代动力学研究：[硕士学位论文].大连：大连医科大学,2008.
[66]郭艳芳.中药纳米雄黄的模板法制备及其生物效应的研究：[硕士学位论文].广西：广西师范大学,2005.
[67]徐凌云.纳米雄黄抗肿瘤作用及其机制研究：[硕士学位论文].武汉：华中科技大学,2003.
[68]Jeff Cummings, Tim H. Ward. Apoptosis pathway-targeted drugs-from the bench to the clinic [J]. Biochimica et Biophysica Acta,2004,1705:53-66
[69]Katja C. Zimmermann.PhD. Doualas R. Green. How cells die:Apoptosis Pathways. [J]. Allergy Clin Immunol,2001,108(4):99-103
[70]Jianhua Zhang, Yingpei Zhang. Caspases, apoptosis and aging [J]. Aging Research Reviews,2003,2:357-366.
[71]Pei-Chin Liao, Chien-Hui Lieu. Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells [J]. Life Sciences,2005,76:1623-1639
[72]Robert S.Sloviter. Apoptosis:a guide for the perplexed [J]. Trends in pharmacological sciences,2002,23(1):19-24.
[73]Brian S. Majors, Michael J. Betenbaugh. Links between metabolism and apoptosis in mammalian cells:Applications for anti-apoptosis engineering [J]. Metabolic Engineering,2007,9:317-326.
[74]Michele Barry, Grant McFadden. Apoptosis regulators from DNA viruses [J]. Current Opinion in Immunology,1998,10:422-430.
[75]卜兴江.细胞凋亡研究进展.[J].生物教学,2006,31(12)：7-9.
[76]王文亮.细胞凋亡研究进展.[J].心脏杂志,2005,17(6),603-606.
[77]卢晓男,石一复.细胞凋亡研究进展. [J].国外医学妇产科学分册,2002,29(2)：96-98.
[78]许艳华.有毒中药诱导肿瘤细胞凋亡研究进展[J].实用中医药杂志,2005,21(4)：247
[79]洪卫,张沂平.中药诱导肿瘤细胞凋亡研究进展[J].浙江中西医结合杂志,2009,19(7)：451-454.
[80]叶星星,蔡志毅,等.细胞周期蛋白G1、G2与恶性肿瘤研究进展[J].温州医学院学报,2011,41(3)：299-301.
[81]Ragion FD. Borriello A, Giordani L, et al. Cell division cycle alterations in human malignancies [J].Cancer,1997,10(1):151-156
[82]David S.Fay. The cell cycle and development:lessons from C.elegans [J]. Cell and Developmental biology,2005,16:397-406.
[83]Man Zhang, Huiling Yang. Negative growth regulators of the cell cycle machinery and cancer [J].Pathophysiology,2009,16:305-309.
[84]Nicolas Tapon, Kenneth H Moberg and Iswar K Hariharan. The coupling of cell growth to the cell cycle [J].
[85]Irene Foster. Cancer:A cell cycle defect [J].Radiography,2008,14:144-149.
[86]肖冬梅,孙关林,等.三氧化二砷对K526细胞细胞周期的影响及其机制的研究[J].中华医学杂志,1999,79(4)：306-307
[87]陈洪,秦叔逵,等.三氧化二砷诱导人肝癌细胞株SMMC7721凋亡的实验研究.[J].肿瘤防治研究,1998,25(5)：336-338.
[1]马子密,傅延龄.历代本草药性汇解[M].北京：中国医药科技出版社,2002：865-867.
[2]国家药典委员会.中华人民共和国药典·2005年一部[S].北京：化学工业出版社,2005：236.
[3]陈思宇,李信民.刘陕西.含砷类中药在恶性血液病治疗中的研究概况[J].中国中药杂志,2000,25(8)：454-457.[4]Lu DP, Qiu JY, Jiang B, et al. Tetrarsenic tetra-sulfide for the treatment of acute promyelocytic leukemia:A pilot report[J]. Blood,2002,99(9); 3136-3143.
[5]CHENSY, LI XM, LIU SX. Over view of the advance in the research of traditional chinese medicine containing arsenic for the treatment of malignant hematologic disease. [J]. China Journal of Chinese Materia Medica,2000,25(8).454-456.
[6]陆道培,邱镜程,陈珊珊,等,口服雄黄治疗急性早幼粒细胞白血病(AML-M3)66例[J].中国实验诊断学,1998,(6)：319.
[7]高学熙,王信淇,马建军.雄黄治疗骨髓异常增生综合征14例[J].临
[8]王梦昌,杨丽红,刘陕西,等.雄黄治疗慢性粒细胞性白血病7例临床观察[J].陕西医学杂志,2002,31(2)：152.
[9]林梅,王子好,张东生.As2S3纳米粒的制备及其对肝癌SMMC-7721细胞的治疗作用.[J].东南大学学报(自然科学版),2006,36：298-302.
[10]王玉华,葛常辉,等.ABC家族基因在乳腺癌耐药细胞MCF-7/ADM中的表达及雄黄对其作用初探[J].解剖学报,2002,33(6)：623-626
[11]邹春芳,张祖贻。As2S2诱导肺腺癌细胞凋亡的实验研究[J].实用肿瘤杂志,2004,19(6)：507-510.
[12]张晨.雄黄对肝癌细胞系BEL-7042增生的影响[J].肝脏,2004,9(2)：112-113
[13]Yin Ling, et al. The Study of Cervical cancer Hela Cell Inhibition and Apoptosis Induced by As4S4 [J].Journal of Methematical Medicine,2007,20(6):785-787
[14]尹伶,濮德敏等.As4s4诱导宫颈癌Hela细胞凋亡及对端粒酶活性的影响[J].中国现代医学杂志,2008,18(3)：298-301
[15]Chen Wenxue,Zhang Feng, et al. The effect of realgar on apoptosis of transplanted ovarian SKOV3 carcinoma cells in nude mice [J].Tumor,2007.27(10):787-790
[16]Jeff Cummings, Tim H. Ward. Apoptosis pathway-targeted drugs-from the bench to the clinic [J]. Biochimica et Biophysica Acta,2004,1705:53-66
[17]Katja C. Zimmermann.PhD. Doualas R. Green. How cells die:Apoptosis Pathways. [J]. Allergy Clin Immunol,2001,108(4):99-103
[18]Jianhua Zhang, Yingpei Zhang. Caspases, apoptosis and aging [J]. Aging Research Reviews,2003,2:357-366.
[19]Pei-Chin Liao, Chien-Hui Lieu. Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells [J]. Life Sciences,2005,76:1623-1639
[20]Robert S.Sloviter. Apoptosis:a guide for the perplexed [J]. Trends in pharmacological sciences,2002,23(1):19-24.
[21]Brian S. Majors, Michael J. Betenbaugh. Links between metabolism and apoptosis in mammalian cells:Applications for anti-apoptosis engineering [J]. Metabolic Engineering,2007,9:317-326.
[22]Michele Barry, Grant McFadden. Apoptosis regulators from DNA viruses [J]. Current Opinion in Immunology,1998,10:422-430.
[23]丁晓辉,董爱红.细胞凋亡与雄黄的临床应用[J].浙江中西医结合杂志,2000,10(5)： 318.
[24]张晨,黄世林,向阳,等.低剂量雄黄诱导NB4细胞凋亡的研究[J].中国中医基础医学杂志,2000,6(2)：11.
[25]钟璐,陈芳源,韩洁英,等.ATRA和雄黄对白血病细胞PML基因及蛋白表达的影响.上海第二医科大学学报,2001,21(2)：106.
[26]陈思宇,刘陕西,张梅,雄黄对急性早幼粒细胞白血病NB4细胞基因表达谱的影响[J].第四军医大学学报,2002,23(6)：1-3.
[27]刘延芳,陆道培,江滨.四硫化四砷对NB4细胞增殖的抑制作用[J].中原医刊,2006,33(12)：3-5.
[28]肖冬梅,孙关林,等.三氧化二砷对K526细胞细胞周期的影响及其机制的研究[J].中华医学杂志,1999,79(4)：306-307
[29]曾芳,雄芳。As4S4对人白血病细胞HL-60细胞COX-2表达和PGE2水平的影响[J].中国现代医药杂志,2007,9(2)：28-31.
[30]尹伶,濮德敏等.As4s4诱导宫颈癌Hela细胞凋亡及对端粒酶活性的影响[J].中国现代医学杂志,2008,18(3)：298-301
[31]刘嵘,濮德敏等。纳米雄黄混悬液对人宫颈癌细胞RCAS1表达的影响[J].中国医院药学杂志,2008,28(6)：459-462.
[32]Sordct O. Mitochondfia. targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. [J].Blood,2001, Jun 15; 97(12):393.
[33]Siu KP,Chan JY,Fung KP. Effect of arsenic trioxide On human hepatocellular carcinoma HepG2 cells:inhibition of proliferation and induction of apoptosis. [J].Life Sci,2002,71(3):275-85.
[34]李国明,王鑫国,李青.雄黄诱导小鼠血细胞凋亡的形态学研究[J].上海医学检验杂志,2000,15(2)：91.
[35]刘京生,吕占军,董兰凤,等.雄黄诱导肿瘤细胞凋亡的实验研究[J].河北中医,2000,22(11)：874.
[36]叶星星,蔡志毅,等.细胞周期蛋白G1、G2与恶性肿瘤研究进展[J].温州医学院学报,2011,41(3)：299-301.
[37]Ragion FD. Borriello A, Giordani L, et al. Cell division cycle alterations in human malignancies [J]. Cancer,1997,10(1):151-156
[38]David S. Fay. The cell cycle and development:lessons from C. elegans [J]. Cell and Developmental biology,2005,16:397-406.
[39]Man Zhang, Huiling Yang. Negative growth regulators of the cell cycle machinery and cancer [J]. Pathophysiology,2009,16:305-309.
[40]Nicolas Tapon, Kenneth H Moberg and Iswar K Hariharan. The coupling of cell growth to the cell cycle [J].
[41]Irene Foster. Cancer:A cell cycle defect [J]. Radiography,2008, 14:144-149.
[42]陈洪,秦叔逵,等.三氧化二砷诱导人肝癌细胞株SMMC7721凋亡的实验研究.[J].肿瘤防治研究,1998,25(5)：336-338.
[43]Rong Liu, Demin PU, et al. Induction of SiHa Cells Apoptosis by Nanometer Realgar Suspension and Its Mechanism [J]. Huazhong Univ Sci Technol [Med Sci],2008,28(3):317-321.
[44]周霭祥,胡晓梅等。青黄散在恶性血液病治疗中的应用[J].中国中西医结合杂志,1981,1(1)：16.
[45]Zhu Q, Zhang JW, et al. Synergic effects of arsenic trioxid and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk [J]. Blood,2002,99(3):1014-1022.
[46]Roboz GJ, Dias S, et al. Arsenic trioxide induce dose and time dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis [J]. Blood,2000,96(4):1525-1530.
[47]梁国刚,张启伟.朱砂、雄黄中各成分的溶解度对其药效、毒副作用的影响[J].中 国中药杂志,2002,27(5)：391-392.
[48]温磊,楼雅卿,江滨,等.四硫化四砷动物药动学研究[J].中国药学杂志,2006,41(8)：619-623.
[49]张伟,余伯阳,寇俊萍,等.雄黄活性物质的毒效相关性初步研究[J].中国天然药物,2004,2(2)：123-125.
[50]岳旺,刘文虎,王兰芬,等.中国矿物药的急性毒性测定[J].中国中药杂志,1989,14(2)：42-45.
[51]周超凡,林育华。传统中药雄黄应用概况及其安全性[J].药物不良反应杂志,2008,10(2)：104-109.
[52]Wang Yan,Qi Li,et al. Research advance of nanometric traditional chinese herbal drugs for cancer treatment [J]. Journal of chinese Integrative Medicine,2007,5(6):697-701
[53]董晓辉.纳米技术应用于中药研究与开发的思考[J].中国中医药信息杂志,2008,15(2)：3-5
[54]朱戈,王振洲等.纳米技术在生物医学领域的应用展望[J].中国医学装备,2011,8(5)：25-27
[55]叶星辰,陈燕忠等。纳米技术在中药新剂型研究中的应用。[J].中国现代药物应用,2011,5(2)：241-243
[56]Peter Balaz, Jan Sedlak.Arsenic in cancer treatment:Challenges for application of Realgar Nanoparticales [J].Toxins,2010,2,1568-1581
[57]孙晓辉.纳米雄黄及其固体分散体的制备和抗肿瘤作用初步观察：[硕士学位论文].武汉：华中科技大学,2003.
[58]石焱.纳米雄黄的制备及药物代谢动力学研究：[硕士学位论文].广州：南方医科大学,2008.
[59]杨晓波.纳米雄黄的制备及其药代动力学研究：[硕士学位论文].大连：大连医科大学,2008.
[60]郭艳芳.中药纳米雄黄的模板法制备及其生物效应的研究：[硕士学位论文].广西：广西师范大学,2005.
[61]徐凌云.纳米雄黄抗肿瘤作用及其机制研究：[硕士学位论文].武汉：华中科技大学,2003.
[62]詹秀琴,赵凤鸣,郭立玮.不同粒径雄黄对SMMC7721细胞凋亡的影响[J].中药药理与临床,2006,22(2)：44-46
[63]徐辉碧,杨祥良,等.雄黄抑制小鼠肉瘤S180的尺寸效应的初步研究[J].武汉大学学报(自然科学版),2000,46：288-289
[64]姜艳丽.纳米雄黄诱导HL-60诱导细胞凋亡的初步研究：[硕士学位论文],佳木斯：佳木斯大学,2005.
[2]Parkin DM, Bray F, Ferlay J et al. Estimating the world cancer burden:globocan 2000 [J].Int J Cancer,2001,94:153-156.
[3]Jemal A, Bray F, Center MM, et al. Global cancer statiscs [J]. CA Cancer J Clin,2011,61(2):69-90
[4]You W, Dainty LA, Rose GS, et al. Gynecologic malignancies in women aged less than 25 years [J]. Obstet Gynecol,2005,105(8):1405-1409.
[5]zur Hausen, H., Papillomaviruses in the causation of human cancers-a brief historical account. Virology,2009.384(2):p.260-5.
[6]Walboommers JM,Jacobs MV,Manos MM,etal.Human papillomavirus is a necessary cause of invasive cancer worldwide[J].J Pathol,1999,189:12-19
[7]F ilippva M, Song H, Connolly JL, et al. The human papillomavirus 16 E6 protein binds to tumor necrosis factor(TNF) R1 and protects cell from TN F2induced apoptosis. BiolChem,2002; 277 (24):21730221739.
[8]Cary A. Moody and Laimonis A. Laimins. Human papillomavirus oncoproteins:pathways to transformation [J]. Nature:cancer,2010,10:550-560
[9]Niladri Ganguly, Suraj P Parihar. Human papillmavirus E6 and E7 oncoproteins as risk factors for tumorigenesis [J]. Biosci,2009,34(1):113-123
[10]Longworth MS,Laimins LA.Pathogenesis of human papillomaviruses in differerntiation epithelia [J]. Microbiol and Mol Biol Rev,2004,68(2):362-372
[11]Band V, Dalal S, et al. Enhanced degradation of P53 protein in HPV-6 and BPV-1 E6 immortalized human mammary epithelial cells [J]. EMBO,1993,12:1847-1852
[12]Crook T, Tidy J A, et al. Degradation of P53 can be targeted by HPV E6 sequences distinct from those required for P53 binding and trans-activation [J].Cell,1991,67:547-556
[13]Havre PA, Yuan J, et al.P53 inactivation by HPV 16 E6 results in increased mutagenesis in human cells [J].Cancer Res,1995,55:4420-4424
[14]Scheffner M, Huibregtse J M, et al.The HPV 16 E6 and E6-AP complex functions as a ubiquitin protein ligase in the ubiquitination of P53 [J].Cell,1993,75:495-505
[15]Scheffner M, Werness B A, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of P53 [J].Cell,1990,63: 1129-1136
[16]Werness B A, Levine A J, et al. Association of human papillomavirus types 16 and 18 E6 proteins with P53 [J].Science,1990,248:76-79
[17]Boyer S N, Wazer D E, Band V. E7 protein of human papillma virus 16 induces the degradation of retinoblastoma protein through ubiquitin-proteasome pathway [J].Cancer Res,1996,56:4620-4624
[18]Dyson N, Howley P M, et al. The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product [J].Science,1989,17:934-937
[19]Eichten A, Westfall M, et al. Stabilization and functional impairment of the tumor suppressor P53 by the human papillomavirus type 16 E7 oncoprotein [J]. Virology, 2002,12:2245-2262
[20]Jo H, Kim J W. Implications of HPV infection in uterine cervical cancer [J].Cancer Ther,2005,3:419-434
[21]Munger K, Howley P M. Human papillomavirus immortalization and transformation functions [J].Virus Res,2002,89:213-228
[22]Munger K, Baldwin A, et al. Mechanisms of human papillomavirus -induced oncogenesis [J].Virol,2004,78:11451-1460
[23]欧幸甘,罗小平等.宫颈癌的新辅助化疗研究进展[J].中国医疗前沿,2010,5(18)：14-16.
[24]Sardi JE, Boixadera MA, Sardi JJ. Neoadjuvant chemotherapy in cervical cancer:a new trend [J].Curt Opin Obstet Gynecol,2005,17(1):43-47.
[25]刘继红,熊樱.对宫颈癌新辅助化疗临床价值的评价[J].中国妇产科临床杂志,2008,9(3)：163-165
[26]苗华芹,周登光等.高危宫颈癌化疗进展[J].实用癌症杂志,2005,20(3)：332-334.
[27]Cai HB, Chen HZ, Yin HH. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical caneer [J]. J Obstet Gynecol Res,2006,32: 315-323.
[28]Sardi JE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage I b squamous carcinoma of the cervix: the final results [J]. Gynecol Onc01,1997,67:61-69.
[29]陈明晖,巫岳鹏.宫颈癌化疗临床研究新进展[J].中国妇幼保健,2005,20：150-1154
[30]Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer:a systematic review and meta analysis of individual patient data from 21 randomised trials [J]. Eur J Cancer,2003,39(17):2470-2486.
[31]Fracasso PM, Blessing JA, Wolf J, et al. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix:a gynecologic oncology group study [J]. Gynecol Oncol,2003,90(1):177-180.
[32]Ya Cao, Ronald A.DePinho, Matthias Ernst, et al. Cancer research:past, present and future [J]. Nature Reviews:cancer,2011,11:749-757
[33]姚志华,张明智.中药抗恶性肿瘤研究进展[J].现代肿瘤医学,2006,14(4)：503-505.
[34]孙端,朱燕飞. 抗肿瘤中药治疗癌症临床概况. [J]. 海峡药学,2010,22(11)：146-148
[35]梁莉,刘叙仪,王洁,等.马蔺子素对耐顾铂人肺腺癌细胞系A549DDP耐药逆转及可能的机制[J].中华医学杂志.2001,81(22)：1392-1393.
[36]林华型.灵芝多糖抗肿瘤靶向作用机制研究进展[J].细胞与分子免疫学杂志,2007.24(4)：428-429.
[37]吕淑华.黄芪多糖抗肿瘤作用研究进展[J].江西中医学院学报,2009,21(1)：85-87.
[38]丁杰龙.川牛膝多糖的抗肿瘤作用初探[J].中国民族民间医药杂志,2009.18(13)：46-47.
[39]张舰,王维民.刘延庆,许运明.南蛇藤提取物体内抗肿瘤作用的实验研究[J].中国中药杂志,2006.31(18)：1514-1516.
[40]陶伟.中药半枝莲的药理及临床应用研究进展[J].海军医学杂志,2008,29(3)：181-184.
[41]陈思宇,李信民.刘陕西.含砷类中药在恶性血液病治疗中的研究概况[J].中国中药杂志,2000,25(8)：454-457.
[42]Lu DP, Qiu JY, Jiang B, et al. Tetrarsenic tetra-sulfide for the treatment of acute promyelocytic leukemia:A pilot report [J]. Blood,2002,99(9); 3136-3143.
[43]邵泽叶,等。纳米三硫化二砷对人骨髓增生异常综合征细胞株MUTZ-1作用的实验研究,中华血液学杂志,2009,1,30(1)：29-32.
[44]CHENSY, LI XM, LIU SX. Over view of the advance in the research of traditional chinese medicine containing arsenic for the treatment of malignant hematologic disease. [J]. China Journal of Chinese Materia Medica,2000,25(8).454-456.
[45]林梅,王子好,张东生.As2S3纳米粒的制备及其对肝癌SMMC-7721细胞的治疗作用.[J].东南大学学报(自然科学版),2006,36：298-302.
[46]王玉华,葛常辉,等.ABC家族基因在乳腺癌耐药细胞MCF-7／ADM中的表达及雄黄对其作用初探[J].解剖学报,2002,33(6)：623-626
[47]邹春芳,张祖贻。As2S2诱导肺腺癌细胞凋亡的实验研究[J].实用肿瘤杂志,2004,19(6)：507-510.
[48]张晨.雄黄对肝癌细胞系BEL-7042增生的影响[J].肝脏,2004,9(2)：112-113
[49]Yin Ling, et al. The Study of Cervical cancer Hela Cell Inhibition and Apoptosis Induced by As4S4 [J].Journal of Methematical Medicine,2007,20(6):785-787
[50]尹伶,濮德敏等.As4s4诱导宫颈癌Hela细胞凋亡及对端粒酶活性的影响[J].中国现代医学杂志,2008,18(3)：298-301
[51]Chen Wenxue,Zhang Feng, et al. The effect of realgar on apoptosis of transplanted ovarian SKOV3 carcinoma cells in nude mice [J].Tumor,2007.27(10):787-790
[52]王玉华,葛常辉。ABC家族基因在乳腺癌耐药细胞MCF-7/ADM中的表达及雄黄对其作用初探[J].解剖学报,2002,33(6)：623-626.
[53]Wang Yan,Qi Li,et al. Research advance of nanometric traditional chinese herbal drugs for cancer treatment [J]. Journal of chinese Integrative Medicine,2007,5(6):697-701
[54]董晓辉.纳米技术应用于中药研究与开发的思考[J].中国中医药信息杂志,2008,15(2)：3-5
[55]朱戈,王振洲等.纳米技术在生物医学领域的应用展望[J].中国医学装备,2011,8(5)：25-27
[56]叶星辰,陈燕忠等。纳米技术在中药新剂型研究中的应用。[J].中国现代药物应用,2011,5(2)：241-243
[57]Peter Balaz, Jan Sedlak.Arsenic in cancer treatment:Challenges for application of Realgar Nanoparticales [J].Toxins,2010,2,1568-1581
[58]詹秀琴,赵凤鸣,郭立玮.不同粒径雄黄对8MMC7721细胞凋亡的影响[J].中药药理与临床,2006,22(2)：44-46
[59]徐辉碧,杨祥良,等.雄黄抑制小鼠肉瘤S180的尺寸效应的初步研究[J].武汉大学学报(自然科学版),2000,46：288-289
[60]姜艳丽.纳米雄黄诱导HL-60诱导细胞凋亡的初步研究：[硕士学位论文],佳木斯：佳木斯大学,2005.
[61]Rong Liu, Demin PU, et al. Induction of SiHa Cells Apoptosis by Nanometer Realgar Suspension and Its Mechanism [J]. Huazhong Univ Sci Technol [Med Sci],2008,28(3):317-321.
[62]刘嵘,濮德敏,等.纳米雄黄混悬液对人宫颈癌细胞RCAS1表达的影响[J].中国医院药学杂志,2008,28(6)：459-462.
[63]孙晓辉.纳米雄黄及其固体分散体的制备和抗肿瘤作用初步观察：[硕士学位论 文].武汉：华中科技大学,2003.
[64]石焱.纳米雄黄的制备及药物代谢动力学研究：[硕士学位论文].广州：南方医科大学,2008.
[65]杨晓波.纳米雄黄的制备及其药代动力学研究：[硕士学位论文].大连：大连医科大学,2008.
[66]郭艳芳.中药纳米雄黄的模板法制备及其生物效应的研究：[硕士学位论文].广西：广西师范大学,2005.
[67]徐凌云.纳米雄黄抗肿瘤作用及其机制研究：[硕士学位论文].武汉：华中科技大学,2003.
[68]Jeff Cummings, Tim H. Ward. Apoptosis pathway-targeted drugs-from the bench to the clinic [J]. Biochimica et Biophysica Acta,2004,1705:53-66
[69]Katja C. Zimmermann.PhD. Doualas R. Green. How cells die:Apoptosis Pathways. [J]. Allergy Clin Immunol,2001,108(4):99-103
[70]Jianhua Zhang, Yingpei Zhang. Caspases, apoptosis and aging [J]. Aging Research Reviews,2003,2:357-366.
[71]Pei-Chin Liao, Chien-Hui Lieu. Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells [J]. Life Sciences,2005,76:1623-1639
[72]Robert S.Sloviter. Apoptosis:a guide for the perplexed [J]. Trends in pharmacological sciences,2002,23(1):19-24.
[73]Brian S. Majors, Michael J. Betenbaugh. Links between metabolism and apoptosis in mammalian cells:Applications for anti-apoptosis engineering [J]. Metabolic Engineering,2007,9:317-326.
[74]Michele Barry, Grant McFadden. Apoptosis regulators from DNA viruses [J]. Current Opinion in Immunology,1998,10:422-430.
[75]卜兴江.细胞凋亡研究进展.[J].生物教学,2006,31(12)：7-9.
[76]王文亮.细胞凋亡研究进展.[J].心脏杂志,2005,17(6),603-606.
[77]卢晓男,石一复.细胞凋亡研究进展. [J].国外医学妇产科学分册,2002,29(2)：96-98.
[78]许艳华.有毒中药诱导肿瘤细胞凋亡研究进展[J].实用中医药杂志,2005,21(4)：247
[79]洪卫,张沂平.中药诱导肿瘤细胞凋亡研究进展[J].浙江中西医结合杂志,2009,19(7)：451-454.
[80]叶星星,蔡志毅,等.细胞周期蛋白G1、G2与恶性肿瘤研究进展[J].温州医学院学报,2011,41(3)：299-301.
[81]Ragion FD. Borriello A, Giordani L, et al. Cell division cycle alterations in human malignancies [J].Cancer,1997,10(1):151-156
[82]David S.Fay. The cell cycle and development:lessons from C.elegans [J]. Cell and Developmental biology,2005,16:397-406.
[83]Man Zhang, Huiling Yang. Negative growth regulators of the cell cycle machinery and cancer [J].Pathophysiology,2009,16:305-309.
[84]Nicolas Tapon, Kenneth H Moberg and Iswar K Hariharan. The coupling of cell growth to the cell cycle [J].
[85]Irene Foster. Cancer:A cell cycle defect [J].Radiography,2008,14:144-149.
[86]肖冬梅,孙关林,等.三氧化二砷对K526细胞细胞周期的影响及其机制的研究[J].中华医学杂志,1999,79(4)：306-307
[87]陈洪,秦叔逵,等.三氧化二砷诱导人肝癌细胞株SMMC7721凋亡的实验研究.[J].肿瘤防治研究,1998,25(5)：336-338.
[1]马子密,傅延龄.历代本草药性汇解[M].北京：中国医药科技出版社,2002：865-867.
[2]国家药典委员会.中华人民共和国药典·2005年一部[S].北京：化学工业出版社,2005：236.
[3]陈思宇,李信民.刘陕西.含砷类中药在恶性血液病治疗中的研究概况[J].中国中药杂志,2000,25(8)：454-457.[4]Lu DP, Qiu JY, Jiang B, et al. Tetrarsenic tetra-sulfide for the treatment of acute promyelocytic leukemia:A pilot report[J]. Blood,2002,99(9); 3136-3143.
[5]CHENSY, LI XM, LIU SX. Over view of the advance in the research of traditional chinese medicine containing arsenic for the treatment of malignant hematologic disease. [J]. China Journal of Chinese Materia Medica,2000,25(8).454-456.
[6]陆道培,邱镜程,陈珊珊,等,口服雄黄治疗急性早幼粒细胞白血病(AML-M3)66例[J].中国实验诊断学,1998,(6)：319.
[7]高学熙,王信淇,马建军.雄黄治疗骨髓异常增生综合征14例[J].临
[8]王梦昌,杨丽红,刘陕西,等.雄黄治疗慢性粒细胞性白血病7例临床观察[J].陕西医学杂志,2002,31(2)：152.
[9]林梅,王子好,张东生.As2S3纳米粒的制备及其对肝癌SMMC-7721细胞的治疗作用.[J].东南大学学报(自然科学版),2006,36：298-302.
[10]王玉华,葛常辉,等.ABC家族基因在乳腺癌耐药细胞MCF-7/ADM中的表达及雄黄对其作用初探[J].解剖学报,2002,33(6)：623-626
[11]邹春芳,张祖贻。As2S2诱导肺腺癌细胞凋亡的实验研究[J].实用肿瘤杂志,2004,19(6)：507-510.
[12]张晨.雄黄对肝癌细胞系BEL-7042增生的影响[J].肝脏,2004,9(2)：112-113
[13]Yin Ling, et al. The Study of Cervical cancer Hela Cell Inhibition and Apoptosis Induced by As4S4 [J].Journal of Methematical Medicine,2007,20(6):785-787
[14]尹伶,濮德敏等.As4s4诱导宫颈癌Hela细胞凋亡及对端粒酶活性的影响[J].中国现代医学杂志,2008,18(3)：298-301
[15]Chen Wenxue,Zhang Feng, et al. The effect of realgar on apoptosis of transplanted ovarian SKOV3 carcinoma cells in nude mice [J].Tumor,2007.27(10):787-790
[16]Jeff Cummings, Tim H. Ward. Apoptosis pathway-targeted drugs-from the bench to the clinic [J]. Biochimica et Biophysica Acta,2004,1705:53-66
[17]Katja C. Zimmermann.PhD. Doualas R. Green. How cells die:Apoptosis Pathways. [J]. Allergy Clin Immunol,2001,108(4):99-103
[18]Jianhua Zhang, Yingpei Zhang. Caspases, apoptosis and aging [J]. Aging Research Reviews,2003,2:357-366.
[19]Pei-Chin Liao, Chien-Hui Lieu. Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells [J]. Life Sciences,2005,76:1623-1639
[20]Robert S.Sloviter. Apoptosis:a guide for the perplexed [J]. Trends in pharmacological sciences,2002,23(1):19-24.
[21]Brian S. Majors, Michael J. Betenbaugh. Links between metabolism and apoptosis in mammalian cells:Applications for anti-apoptosis engineering [J]. Metabolic Engineering,2007,9:317-326.
[22]Michele Barry, Grant McFadden. Apoptosis regulators from DNA viruses [J]. Current Opinion in Immunology,1998,10:422-430.
[23]丁晓辉,董爱红.细胞凋亡与雄黄的临床应用[J].浙江中西医结合杂志,2000,10(5)： 318.
[24]张晨,黄世林,向阳,等.低剂量雄黄诱导NB4细胞凋亡的研究[J].中国中医基础医学杂志,2000,6(2)：11.
[25]钟璐,陈芳源,韩洁英,等.ATRA和雄黄对白血病细胞PML基因及蛋白表达的影响.上海第二医科大学学报,2001,21(2)：106.
[26]陈思宇,刘陕西,张梅,雄黄对急性早幼粒细胞白血病NB4细胞基因表达谱的影响[J].第四军医大学学报,2002,23(6)：1-3.
[27]刘延芳,陆道培,江滨.四硫化四砷对NB4细胞增殖的抑制作用[J].中原医刊,2006,33(12)：3-5.
[28]肖冬梅,孙关林,等.三氧化二砷对K526细胞细胞周期的影响及其机制的研究[J].中华医学杂志,1999,79(4)：306-307
[29]曾芳,雄芳。As4S4对人白血病细胞HL-60细胞COX-2表达和PGE2水平的影响[J].中国现代医药杂志,2007,9(2)：28-31.
[30]尹伶,濮德敏等.As4s4诱导宫颈癌Hela细胞凋亡及对端粒酶活性的影响[J].中国现代医学杂志,2008,18(3)：298-301
[31]刘嵘,濮德敏等。纳米雄黄混悬液对人宫颈癌细胞RCAS1表达的影响[J].中国医院药学杂志,2008,28(6)：459-462.
[32]Sordct O. Mitochondfia. targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. [J].Blood,2001, Jun 15; 97(12):393.
[33]Siu KP,Chan JY,Fung KP. Effect of arsenic trioxide On human hepatocellular carcinoma HepG2 cells:inhibition of proliferation and induction of apoptosis. [J].Life Sci,2002,71(3):275-85.
[34]李国明,王鑫国,李青.雄黄诱导小鼠血细胞凋亡的形态学研究[J].上海医学检验杂志,2000,15(2)：91.
[35]刘京生,吕占军,董兰凤,等.雄黄诱导肿瘤细胞凋亡的实验研究[J].河北中医,2000,22(11)：874.
[36]叶星星,蔡志毅,等.细胞周期蛋白G1、G2与恶性肿瘤研究进展[J].温州医学院学报,2011,41(3)：299-301.
[37]Ragion FD. Borriello A, Giordani L, et al. Cell division cycle alterations in human malignancies [J]. Cancer,1997,10(1):151-156
[38]David S. Fay. The cell cycle and development:lessons from C. elegans [J]. Cell and Developmental biology,2005,16:397-406.
[39]Man Zhang, Huiling Yang. Negative growth regulators of the cell cycle machinery and cancer [J]. Pathophysiology,2009,16:305-309.
[40]Nicolas Tapon, Kenneth H Moberg and Iswar K Hariharan. The coupling of cell growth to the cell cycle [J].
[41]Irene Foster. Cancer:A cell cycle defect [J]. Radiography,2008, 14:144-149.
[42]陈洪,秦叔逵,等.三氧化二砷诱导人肝癌细胞株SMMC7721凋亡的实验研究.[J].肿瘤防治研究,1998,25(5)：336-338.
[43]Rong Liu, Demin PU, et al. Induction of SiHa Cells Apoptosis by Nanometer Realgar Suspension and Its Mechanism [J]. Huazhong Univ Sci Technol [Med Sci],2008,28(3):317-321.
[44]周霭祥,胡晓梅等。青黄散在恶性血液病治疗中的应用[J].中国中西医结合杂志,1981,1(1)：16.
[45]Zhu Q, Zhang JW, et al. Synergic effects of arsenic trioxid and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk [J]. Blood,2002,99(3):1014-1022.
[46]Roboz GJ, Dias S, et al. Arsenic trioxide induce dose and time dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis [J]. Blood,2000,96(4):1525-1530.
[47]梁国刚,张启伟.朱砂、雄黄中各成分的溶解度对其药效、毒副作用的影响[J].中 国中药杂志,2002,27(5)：391-392.
[48]温磊,楼雅卿,江滨,等.四硫化四砷动物药动学研究[J].中国药学杂志,2006,41(8)：619-623.
[49]张伟,余伯阳,寇俊萍,等.雄黄活性物质的毒效相关性初步研究[J].中国天然药物,2004,2(2)：123-125.
[50]岳旺,刘文虎,王兰芬,等.中国矿物药的急性毒性测定[J].中国中药杂志,1989,14(2)：42-45.
[51]周超凡,林育华。传统中药雄黄应用概况及其安全性[J].药物不良反应杂志,2008,10(2)：104-109.
[52]Wang Yan,Qi Li,et al. Research advance of nanometric traditional chinese herbal drugs for cancer treatment [J]. Journal of chinese Integrative Medicine,2007,5(6):697-701
[53]董晓辉.纳米技术应用于中药研究与开发的思考[J].中国中医药信息杂志,2008,15(2)：3-5
[54]朱戈,王振洲等.纳米技术在生物医学领域的应用展望[J].中国医学装备,2011,8(5)：25-27
[55]叶星辰,陈燕忠等。纳米技术在中药新剂型研究中的应用。[J].中国现代药物应用,2011,5(2)：241-243
[56]Peter Balaz, Jan Sedlak.Arsenic in cancer treatment:Challenges for application of Realgar Nanoparticales [J].Toxins,2010,2,1568-1581
[57]孙晓辉.纳米雄黄及其固体分散体的制备和抗肿瘤作用初步观察：[硕士学位论文].武汉：华中科技大学,2003.
[58]石焱.纳米雄黄的制备及药物代谢动力学研究：[硕士学位论文].广州：南方医科大学,2008.
[59]杨晓波.纳米雄黄的制备及其药代动力学研究：[硕士学位论文].大连：大连医科大学,2008.
[60]郭艳芳.中药纳米雄黄的模板法制备及其生物效应的研究：[硕士学位论文].广西：广西师范大学,2005.
[61]徐凌云.纳米雄黄抗肿瘤作用及其机制研究：[硕士学位论文].武汉：华中科技大学,2003.
[62]詹秀琴,赵凤鸣,郭立玮.不同粒径雄黄对SMMC7721细胞凋亡的影响[J].中药药理与临床,2006,22(2)：44-46
[63]徐辉碧,杨祥良,等.雄黄抑制小鼠肉瘤S180的尺寸效应的初步研究[J].武汉大学学报(自然科学版),2000,46：288-289
[64]姜艳丽.纳米雄黄诱导HL-60诱导细胞凋亡的初步研究：[硕士学位论文],佳木斯：佳木斯大学,2005.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |